Every man desires to have a perfectly sculpted figure. When men see their six-pack abs, bulging biceps, and perfectly formed calves reflected in the mirror, they cannot help but feel better about ...

The European Medicines Agency (EMA) has recommended approval of Somatropin Biopartners (BioPartners), a new recombinant human growth hormone (rhGH) for long-term treatment of growth failure in ...

The product, lonapegsomatropin, is a sustained-release formulation and could replace daily injections. The FDA recently approved the first once-weekly somatropin injection for pediatric patients 1 ...

Ascendis Pharma A/S (NASDAQ:ASND) released topline results from Phase 3 foresiGHt trial to compare the efficacy and safety of TransCon hGH (lonapegsomatropin) with placebo and daily hGH (human growth ...

A ribbons model of Human Growth Hormone, also known as Somatotropin, with a translucent surface model. The FDA has granted Orphan Drug designation to TransCon hGH (lonapegsomatropin; Ascendis Pharma), ...

COPENHAGEN, Denmark, July 28, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has approved SKYTROFA ® (lonapegsomatropin-tcgd ...

Somatropin, also known as human growth hormone (HGH), is a synthetic version of the naturally occurring hormone produced by the pituitary gland. It plays a crucial role in various physiological ...

The HGH-X2 formula is designed to aid in the “release” of human growth hormone, which is generated by the pituitary gland. It’s important to note that this supplement does not include any HGH, which ...

The approval was based on data from the phase 3 heiGHt trial that assessed Skytrofa in 161 treatment-naïve, prepubertal patients with growth hormone deficiency. The Food and Drug Administration has ...

Sandoz launches somatropin, the first-ever Japanese biosimilar, increasing access to key medicines in second largest global market Human growth hormone somatropin launch follows precedent-setting ...

Ascendis Pharma announced positive results from the Week 26 analysis of its Phase 2 trial, New InsiGHTS, which studied once-weekly TransCon hGH for prepubertal children with Turner syndrome. The trial ...

First of many planned label expansions supporting Vision 2030 goal to become the leading endocrinology rare disease company On track to initiate basket trial for ISS, SHOX deficiency, Turner syndrome, ...